BioCentury
ARTICLE | Finance

Gene therapies in Sync

How two new investments shore up Syncona’s gene therapy plan

June 14, 2018 6:03 AM UTC

With the launch of a pair of new start-ups, Syncona Ltd. (LSE:SYNC) has invested in a CNS play and a new ophthalmic approach, bringing the U.K. firm’s gene therapy portfolio to five.

Syncona invested $23 million toward a $25 million series A round for SwanBio Therapeutics Ltd., which is taking aim at undisclosed CNS disorders. Partners Innovation Fund provided the balance...